摘要
目的探讨非小细胞肺癌EGFR基因检测及EGFR-TKI治疗疗效。方法回顾性分析2016年8月~2019年2月期间90例行EGFR基因检测的90例非小细胞肺癌患者的病例资料,并根据检测结果,分为突变并靶向治疗组,野生普通化疗组;突变靶向治疗组:EGFR有突变并使用EGFR-TKI治疗,野生普通化疗组:EGFR未突变并采用普通化疗组,对比两组患者疾病控制情况。结果90例患者中,共35例患者出现EGFR基因突变,占38.88%。其中38例肿瘤组织的大标本中,EGFR基因突变15例,占39.47%;52例血浆组织的标本中,EGFR基因突变20例,占38.46%,两组不同来源的标本EGFR基因突变率无显著差异(P>0.05)。其中19del突变10例,L858R突变24例,19del+L858R1例,未检测到外显18、20点出现突变情况;突变组患者的疾病缓解率为77.14%,明显高于野生组的32.73%(P<0.05)。结论针对非小细胞肺癌患者,对其进行EGFR基因检测有助于判断患者突变阳性率,从而采取有效的治疗措施,控制疾病的发展;EGFR-TKI疗法取得的治疗效果显著,而检测患者的EGFR基因,有助于预测EGFR-TKI治疗疾病的效果。
Objective To investigate the effect of EGFR gene detection and egfr-tki therapy on non-small cell lung cancer. Methods the data of 90 patients with non-small cell lung cancer who underwent 90 routine EGFR gene tests in our hospital from August 2016 to February 2019 were retrospectively analyzed. Mutation-targeted therapy group: patients with EGFR mutation and treated with egfr-tki;wild common chemotherapy group: patients without EGFR mutation and treated with common chemotherapy group;disease control status of the two groups was compared. Results among the 90 patients,35 patients had EGFR gene mutation,accounting for 38.88%. Among the 38 large samples of tumor tissues,15( 39.47%) had EGFR gene mutation. Among the 52 plasma tissue samples,20 were EGFR gene mutations,accounting for 38.46%,and the EGFR gene mutation rate of the samples from different sources in the two groups was not significant( P > 0.05). There were 10 cases of 19del mutation,24 cases of L858R mutation,and 19del + L858R1 mutation. The disease remission rate of 77.14% in the mutant group was significantly higher than that of 32.73% in the wild group( P < 0.05). Conclusion for patients with NSCLC, EGFR gene test is helpful to determine the mutation positive rate of patients,so as to take effective treatment measures and control the development of the disease. Egfr-tki has produced significant therapeutic results,and testing the EGFR gene in patients can help predict the efficacy of egfr-tki in treating disease.
作者
徐烨
周卫东
谭为
XU Ye;ZHOU Wei-dong;TAN Wei(Yichun people's hospital,Jiangxi 336000,China)
出处
《中国处方药》
2019年第10期167-168,共2页
Journal of China Prescription Drug
基金
江西省宜春市科技计划项目（JXYC2016KSA004）
